Trials / Completed
CompletedNCT00245310
Indocyangreen Elimination in Cirrhosis and Acute Liver Failure
Evaluation of the Indocyangreen Elimination as a Prognostic Marker in Decompensated Cirrhosis and Acute Liver Failure
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 40 (estimated)
- Sponsor
- Heidelberg University · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Indocyangreen (ICG)is totally biliary eliminated and corresponds to hepatocyte function and liver perfusion. The ICG-clearance will be evaluated as a prognostic marker in liver disease.
Detailed description
patients with acute liver failure or advanced liver disease will be studied. ICG-clearance will be correlated with established clinical scores and outcome.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Indocyangreen (ICG) clearance |
Timeline
- Start date
- 2005-10-01
- Primary completion
- 2010-10-01
- Completion
- 2010-10-01
- First posted
- 2005-10-27
- Last updated
- 2010-10-11
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT00245310. Inclusion in this directory is not an endorsement.